Skip to main content

Carbonylated cardiac myosin binding protein as a potential biomarker of doxorubicin-induced cardiotoxicity

Wednesday, November 06, 2013 — Poster Session I

4:00 p.m. – 6:00 p.m.

FAES Academic Center (Upper-Level Terrace)




  • B. P. Aryal
  • J. Jeong
  • V. A. Rao


Doxorubicin (Dox) is an anthracycline drug that is effectively used as a chemotherapeutic agent for various malignancies. Its dose-dependent oxidative stress and irreversible cardiac damage, however, has limited its chemoprotective properties in clinical practice. We hypothesized that the consequent protein oxidation under oxidative stress can be monitored and correlated with cellular outcome of survival or death. Based on our findings, we focused on protein carbonylation as an indicator of severe oxidative damage. First, to understand how Dox-induced oxidative stress is related to the cardiotoxicity, we detected a specific cardiac protein that was carbonylated under Dox-induced oxidative stress in a spontaneously hypertensive rat (SHR) model of acute toxicity. We identified this protein as a cardiac myosin binding protein C (MyBPC) using mass spectrometry. Consistent with the in vivo results, recombinant MyBPC also showed an increase in carbonylation under excessive oxidative conditions. We will present current evidence on the carbonylation of MyBPC in the context of its degradation under cardiotoxic conditions. Data from studies on the functional consequences of carbonylation in vitro will also be presented. Overall, our findings indicate the potential for a specific oxidative biomarker for monitoring the Dox-induced cardiotoxicity.

back to top